# Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers

> **NCT00255359** · PHASE1 · WITHDRAWN · sponsor: **Hadassah Medical Organization** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Hepatitis C Virus Infection

## Interventions

- **DRUG:** XTL-2125

## Key facts

- **NCT ID:** NCT00255359
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2007-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255359, "Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00255359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*